gout

News

Arthrosi drug trial in gout delivers for new owner Sobi

Sobi's $1.5 billion takeover of Arthrosi at the end of 2025 has started to pay off, with a positive phase 3 trial for gout therapy pozdeutinurad.

News

Sobi pays $1.5bn for Arthrosi to grow in gout

Sobi has hit the acquisition trail with a deal to buy Arthrosi Therapeutics for up to $1.5 billion, adding a drug in late-stage testing for gout.

News

$refractory chronic gout$

Sobi starts rolling FDA filing for chronic gout drug

Sweden’s Sobi has kicked off a rolling biologics license application in the US for SEL-212, vying to become a new option for patients with refractory chronic gout that doesn’t respond to cu

News

Sobi plans filings for gout drug after phase 3 readout

SEL-212 will compete with Horizon's fast-growing Krystexxa if approved by the FDA.

News

AZ considers options as US gout drug deal backfires

Ironwood tears up licensing agreement after sales disappoint

News

FDA approves Ironwood's gout combination drug

Good news for Ironwood, which forecast annual sales of up to $300m, despite black box kidney failure warning.

Arthrosi drug trial in gout delivers for new owner Sobi

Sobi pays $1.5bn for Arthrosi to grow in gout

Sobi starts rolling FDA filing for chronic gout drug

Sobi plans filings for gout drug after phase 3 readout

AZ considers options as US gout drug deal backfires

FDA approves Ironwood's gout combination drug

ASCO 2026: Chinese firms take a front seat in oncology, with...

Discover a new era of healthcare panel engagement: Grounded ...

gout

Editor's Picks